Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
13 août 2024 09h07 HE
|
Aclarion, Inc.
Vitality is a top 4 Provider of Private Medical Insurance in the UK.Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health Insurers in the UK.Nearly 60% of all Patients With Private...
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
09 juil. 2024 07h00 HE
|
Aclarion, Inc.
Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care...
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
26 juin 2024 08h30 HE
|
Aclarion, Inc.
AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First...
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
25 juin 2024 08h30 HE
|
Aclarion, Inc.
Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract...
Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
25 avr. 2024 09h14 HE
|
Aclarion, Inc.
LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system ...
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
04 mars 2024 08h00 HE
|
Aclarion, Inc.
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting...
Aclarion Announces Closing of $3.0 Million Public Offering
27 févr. 2024 15h22 HE
|
Aclarion, Inc.
BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...
Aclarion Announces Pricing of $3.0 Million Public Offering
26 févr. 2024 09h15 HE
|
Aclarion, Inc.
BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
05 févr. 2024 08h00 HE
|
Aclarion, Inc.
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical...
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
22 janv. 2024 08h00 HE
|
Aclarion, Inc.
Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute Dr. Uribe Becomes...